Researchers in the Schools of Medicine and Engineering at Vanderbilt University have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts.

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

Jonathan Lehman, M.D., Ph.D., instructor in Medicine in the Division of Hematology/Oncology, has received a Career Development Award from LUNGevity, a nonprofit organization that provides support programs for lung cancer patients and families, public education and funding for innovative scientific research.

Vanderbilt University Medical Center has been designated a Lung Cancer Screening Center by the American College of Radiology.

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.

A microRNA — a small piece of RNA involved in regulating gene expression — functions as an oncogene to drive the development of lung cancer, Vanderbilt University investigators have discovered.

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been awarded a V Scholar Grant from the V Foundation for Cancer Research.